‌

US Patent 11396513 Compositions for activating pyruvate kinase

Patent 11396513 was granted and assigned to FORMA Therapeutics on July, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

FORMA Therapeutics

0

Current Assignee

FORMA Therapeutics

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

David R. Lancia, Jr.0

Gary Gustafson0

Lorna Mitchell0

Neal Green0

Tatiana Shelekhin0

Xiaozhang Zheng0

Date of Patent

July 26, 2022

0

Patent Application Number

170620590

Date Filed

October 2, 2020

0

Patent Citations

US Patent 10695330 Methods of treatment

US Patent 10004725 Methods of treatment

US Patent 10017491 Compounds and uses thereof for the modulation of hemoglobin

0

US Patent 10034879 Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation

0

US Patent 10077249 Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde

US Patent 10100040 Compounds and uses thereof for the modulation of hemoglobin

US Patent 10100043 Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation

US Patent 10208052 Compositions for activating pyruvate kinase

...

Patent Primary Examiner

0

Compositions for the activation of PKR are provided, as well as therapeutic administration of the compositions for the treatment of pyruvate kinase-related medical conditions, such as pyruvate kinase deficiency (PKD).

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11396513 Compositions for activating pyruvate kinase

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.